Roivant looks to quickly turn the page, starting with a Phase 3 win

 A new hormonal therapy designed to treat uterine fibroids called relugolix has finished a Phase 3 study in Japan, and the results are positive. That’s welcome news for a SoftBank-backed company based in Basel, Switzerland called Roivant Sciences that’s separately dealing with much lousier news. Read More

Responses are currently closed, but you can trackback from your own site.

Comments are closed.